'Dexanabinol' may Treat Brain Cancer

by Bidita Debnath on  October 2, 2012 at 9:57 PM Research News   - G J E 4
In a US cancer centre, researchers are evaluating the safety and tolerability of a synthetic cannabinoid called dexanabinol (ETS2101).

Delivered as a weekly intravenous infusion, the drug is being tested in patients with all forms of brain cancer, both primary and metastatic.
 'Dexanabinol' may Treat Brain Cancer
'Dexanabinol' may Treat Brain Cancer

"In this Phase I study, we are examining the safety of multiple doses of dexanabinol, extent of penetration into the brain, and suitability for future trials," Santosh Kesari, MD, PhD, principal investigator, and director of neuro-oncology, UC San Diego Moores Cancer Center, said.

"What we hope to determine is the safe and optimal dose of drug in the brain," Kesari said.

Dexanabinol is a cannabinoid derivative that causes no psychotropic effects.

It was tested previously as a neuroprotective in patients with traumatic brain injury.

During these trials the drug was found to cross the blood-brain barrier.

More recently, researchers at e-Therapeutics plc, who are supporting the current trial, showed that dexanabinol kills cultured cancer cells derived from many tumor types.

Additional research in Kesari's lab demonstrated the drug's anti-cancer effects in patient-derived brain cancer cell lines.

Source: ANI

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

View All